Screening for Hematology Branch Protocols (NCT00001620) | Clinical Trial Compass
By InvitationNot Applicable
Screening for Hematology Branch Protocols
United States10,000 participantsStarted 1996-12-31
Plain-language summary
This study allows the evaluation of subjects in order to determine their ability to safely participate in other active research studies.
After subjects complete the screening process, they will be offered the opportunity to participate in an active research study, or if no appropriate studies are available information and recommendations will be provided for other treatment options.
Who can participate
Age range
2 Years – 100 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
* INCLUSION CRITERIA:
Subjects will be entered on this protocol at the time of their first visit to the NIH Clinical Center outpatient clinic or inpatient service if:
The subject carries the diagnosis of a disorder for which the NHLBI has an active research protocol, and based on information received from an outside physician, he/she appears to meet at least preliminary eligibility criteria for that protocol.
OR
The subject is a donor for a subject for which the NHLBI has an active stem cell transplant protocol and based on information received from an outside physician, he/she appears to meet preliminary eligibility as a donor.
OR
The subject is a normal volunteer for which the NHLBI has an active study recruiting healthy normal volunteers and he/she appears to meet preliminary eligibility as a normal volunteer.
Age greater than or equal to 2 and Weight greater than 12 kg. (Healthy Volunteer age greater than or equal to 8)
The subject, the subject s guardian (if the subject is a minor), or the subject s legally authorized representative (LAR) is capable of informed consent, and willing to sign the consent form after initial counseling by clinical staff. Separate consent forms for all interventional or surgical procedures will be obtained after explanation of the specific procedure.
EXCLUSION CRITERIA:
All subjects not fulfilling the inclusion criteria will be considered ineligible.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Since this study is enrolling by invitation only, can you help me understand whether I might be eligible to be referred or invited to participate, and what criteria the Hematology Branch typically uses to extend those invitations?
2This trial is described as a screening study rather than a treatment study — does that mean it's mainly used to determine if I qualify for other Hematology Branch protocols, and if so, which of those other studies might be relevant to my specific condition?
3The primary outcomes here involve clinical exams, imaging, and lab assessments — can you walk me through what kinds of tests I should expect, and are any of them more invasive or burdensome than what I'm already undergoing for my diagnosis?
4Since this is a Phase NA screening study, it isn't directly testing a new treatment — should I be pursuing standard treatment options at the same time, or would participating in this screening process potentially open doors to treatments I can't access elsewhere?
5If I participate in this screening study and am found eligible for a Hematology Branch treatment protocol, what would the next steps look like, and how quickly would I need to make a decision about enrolling in that follow-on study?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Primary endpoint is the results of clinical, imaging and laboratory assessments.
Timeframe: ongoing
Trial details
NCT IDNCT00001620
SponsorNational Heart, Lung, and Blood Institute (NHLBI)